Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide

Journal of Bone and Mineral Research

Volumn 22, Issue 6, 2007, Pages 841-848

  Chen, Peiqi ^a   Jerome, Christopher P ^b   Burr, David B ^c   Turner, Charles H ^c   Ma, Yanfei L ^a   Rana, Asad ^a   Sato, Masahiko ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Think Bone Consulting Inc   (United States)

^c INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone biopsy; Bone microarchitecture; Bone strength; Histomorphometry; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE BIOPSY; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; ILIAC CREST; LUMBAR VERTEBRA; MONKEY; MORPHOMETRICS; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RISK REDUCTION; STATISTICAL ANALYSIS; ANIMAL; BONE; COMPRESSIVE STRENGTH; DRUG EFFECT; HISTOLOGY; ILIAC BONE; MACACA; PHYSIOLOGY;

ANIMALS; BIOMECHANICS; BONE AND BONES; COMPRESSIVE STRENGTH; FEMALE; FEMUR NECK; ILIUM; LUMBAR VERTEBRAE; MACACA FASCICULARIS; OVARIECTOMY; TERIPARATIDE;

EID: 34548222683     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.070310     Document Type: Article

References (31)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 344:1434-1441.
2. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853.
3. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941.
4. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF 2006 Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855-864.
5. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768.
6. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R 2001 Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150-159.
7. Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, Brommage R, Turner CH 2000 Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 11:871-880.
8. Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH 2004 Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623-629.
9. Turner CH, Burr DB, Hock JM, Brommage R, Sato M 2001 The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys. In: Majumdar S (ed.) Non-Invasive Assessment of Trabecular Bone Architecture and the Competence of Bone. Plenum, New York, NY, USA, pp. 165-179.
10. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
11. Keshawarz NM, Recker RR 1984 Expansion of the medullary cavity at the expense of cortex in postmenopausal osteoporosis. Metab Bone Dis Rel Res 5:223-228.
12. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM 2001 Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165.
13. Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: A tutorial. Bone 14:595-608.
14. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970.
15. Delmas PD, Hardy P, Garnero P, Dain M 2000 Monitoring individual response to hormone replacement therapy with bone markers. Bone 26:553-560.
16. Garnero P, Darte C, Delmas PD 1999 A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 24:603-609.
17. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD 2000 Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434-442.
18. Vesterby A, Mosekilde L, Gundersen HJG, Melsen F, Mosekilde L, Holme K, Sørensen S 1991 Biologically meaningful determinants of the in vitro strength of lumbar vertebrae. Bone 12:219-224.
19. Amling M, Herden S, Posl M, Hahn M, Ritzel H, Delling G 1996 Heterogeneity of the skeleton: Comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J Bone Miner Res 11:36-45.
20. Dempster DW, Ferguson-Pell MW, Mellish RW, Cochran GV, Xie F, Fey C, Horbert W, Parisien M, Lindsay R 1993 Relationships between bone structure in the iliac crest and bone structure and strength in the lumbar spine. Osteoporos Int 3:90-96.
21. Mosekilde L, Mosekilde L 1988 Iliac crest trabecular bone volume as predictor for vertebral compressive strength, ash density and trabecular bone volume volume in normal individuals. Bone 9:195-199.
22. Thomsen JS, Ebbesen EN, Mosekilde L 2002 Predicting human vertebral bone strength by vertebral static histomorphometry. Bone 30:502-508.
23. Cendre E, Mitton D, Roux JP, Arlot ME, Duboeuf F, Burt-Pichat B, Rumelhart C, Peix G, Meunier PJ 1999 High-resolution computed tomography for architectural characterization of human lumbar cancellous bone: Relationships with histomorphometry and biomechanics. Osteoporos Int 10:353-360.
24. Chalmers J, Weaver JK 1966 Cancellous bone: Its strength and changes with aging and an evaluation of some methods for measuring its mineral content. II. An evaluation of some methods for measuring osteoporosis. J Bone Joint Surg Am 48:299-308.
25. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD 2004 Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736-746.
26. Recker RR, Resch H, Chen P, Misurski DA, Pavo I, Sipos AA 2006 Relationship between teriparatide-mediated changes in BMD and microarchitecture in postmenopausal women with osteoporosis. Osteoporos Int 17(Suppl 2):S87.
27. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH 2006 Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21:1785-1790.
28. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
29. Li Z, Meredith MP, Hoseyni MS 2001 A method to assess the proportion of treatment effect explained by a surrogate end-point. Stat Med 20:3175-3188.
30. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10.
31. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261.